Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.
about
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study.A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation.Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients.Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III studyTailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.Therapeutic drug monitoring for imatinib: Current status and Indian experience.Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients.A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib.Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?Do we have to kill the last CML cell?Navigating the road toward optimal initial therapy for chronic myeloid leukemia.Predicting the response of CML patients to tyrosine kinase inhibitor therapy.Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.Molecular resistance: an early indicator for treatment change?Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring.Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells.Toward a cure for chronic myeloid leukemia.Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia.No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
P2860
Q33394772-7B0D90FD-8C8C-4853-B7F5-670F07F4AD71Q33416063-E383247F-4D54-455B-8D78-30C1208DA227Q33427392-9C2304B7-0214-4AC6-95C1-CB7033FF5D27Q33557847-7A1A69AD-3829-4BAB-A645-AFB543BC47A8Q34525644-7AB844D0-D8D9-4DEB-A2DC-C0DAE02BEFE5Q34792645-339A89F1-F7FF-4887-BD26-2F9428D30268Q36364850-DD8F6EC0-47E2-41A4-BB4E-82D9982D146DQ36478229-3E6C581D-EB33-4BB1-A313-DECE18C368A0Q36933601-EA2C5027-8A3D-46E6-8722-4762CEA01732Q37428659-3F419B2D-2997-4DAF-95C7-27BE49801AD1Q37517632-B9F93CA4-A521-4490-8DC4-EA910D1C9F3DQ37630453-F33C8F63-9919-4E34-B4BA-3CBDA4FB41D5Q37722753-E1788E5D-6DF8-436C-B6C3-2D6784797B11Q37731289-7EB46121-84D4-4903-B51F-2E92E3A65E73Q37789148-6B35C035-E0B7-47B0-B372-FD4F4682BA8FQ37831034-01D50F73-55CC-4FAC-9076-D717E7DAE358Q37859303-52A0FF5C-0EAD-48EF-AE4C-964F352BDC7CQ37862942-70E523C9-67B4-48C4-9906-9007150815B7Q37896015-8B98557F-B9D0-4794-88A1-B031D0A4EBA4Q37979587-4200B7D2-B918-462E-8C08-364F415E3BFDQ38095956-FA7590B2-9B95-45EF-8FAE-A553F689CD37Q38910072-C4838BED-13A2-45CF-BDBA-DEB159C3BF92Q39843822-78C76223-0F9E-4B34-91C4-DA0A632CC23FQ41978950-325FCF8F-2E88-41AF-A98B-01A59B5E85A6Q42845531-897AE605-3C86-432C-878A-78120682622CQ44027139-9963ABD5-CF2C-440C-87E5-DAA4B9D46930Q46573433-D9727B24-9100-4A0C-ADAF-C6F9540BC4B5Q48189225-D07A586F-C549-4D5B-9B34-1F3F3FF0D8D5Q51251518-86ACC26A-F1A6-4ED0-B6F4-7E5BB4997C19
P2860
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Cytogenetic and molecular resp ...... trough imatinib plasma levels.
@en
Cytogenetic and molecular resp ...... trough imatinib plasma levels.
@nl
type
label
Cytogenetic and molecular resp ...... trough imatinib plasma levels.
@en
Cytogenetic and molecular resp ...... trough imatinib plasma levels.
@nl
prefLabel
Cytogenetic and molecular resp ...... trough imatinib plasma levels.
@en
Cytogenetic and molecular resp ...... trough imatinib plasma levels.
@nl
P2093
P1433
P1476
Cytogenetic and molecular resp ...... trough imatinib plasma levels
@en
P2093
Clayton A Smith
Cynthia L Toze
Donna E Hogge
Donna L Forrest
Heather J Sutherland
John D Shepherd
Julye C Lavoie
Kevin W Song
Maryse M Power
Michael J Barnett
P304
P356
10.1016/J.LEUKRES.2008.07.015
P577
2008-08-31T00:00:00Z